Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flunisolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.73 |
| ▸ | PGR | P06401 | 8/20 | 0.73 |
| ▸ | LMNA | P02545 | 6/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.73 |
| ▸ | AR | P10275 | 4/20 | 0.73 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocinolone Acetonide SCHEMBL2251974 | 0.94 | NR3C1 (0.82) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Flunisolide SCHEMBL20915050 | 0.92 | CYP3A4 (0.69) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Flumethasone SCHEMBL2860002 | 0.91 | PGR (0.81) | PGRNR3C1HIF1ACYP3A4AR | |
| Flurandrenolide SCHEMBL28086640 | 0.91 | HIF1A (0.69) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Flunisolide SCHEMBL9987242 | 0.87 | CYP3A4 (0.61) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Fluocinolone Acetonide SCHEMBL8450831 | 0.86 | NR3C1 (0.77) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Triamcinolone Acetonide SCHEMBL20915153 | 0.86 | HIF1A (0.77) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Fluocinolone Acetonide SCHEMBL5501859 | 0.86 | HIF1A (0.77) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Fluticasone Propionate SCHEMBL1692016 | 0.85 | NR3C1 (0.67) | PGRNR3C1LMNAHIF1ACYP3A4 | |
| Fluocinolone Acetonide SCHEMBL11911287 | 0.85 | NR3C1 (1.00) | PGRNR3C1LMNAHIF1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160128944-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME THERAPEUTICS LIMITED (IN) | 2016-05-12 | — | — | US | claimed |
| EP-3003031-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | Vyome Biosciences Pvt Ltd (IN) | 2016-04-13 | — | — | EP | claimed |
| WO-2014195872-A1 | COATED PARTICLES AND COMPOSITIONS COMPRISING SAME | VYOME BIOSCIENCES PVT. LTD. (IN) | 2014-12-11 | — | — | WO | claimed |
| WO-2011082290-A2 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, AND ASPIRIN | ORGANOMED CORPORATION (US) | 2011-07-07 | — | — | WO | claimed |
| WO-2024124117-A1 | EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4380553-A1 | STABILISED COMPOSITIONS | Rumin8 Pty Ltd (AU) | 2024-06-12 | — | — | EP | disclosed |
| WO-2024107937-A1 | ANTIMICROBIAL COATING FOR MEDICAL DEVICES WITH HIGH ELECTROCONDUCTIVITY AND BIOCOMPATIBILITY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024020592-A1 | COSMETIC OR PERSONAL CARE COMPOSITION COMPRISING RECOMBINANT MILK PROTEIN | Perfect Day, Inc. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-11819578-B2 | Nanofiber scaffolds | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023192969-A1 | METHOD FOR TREATING CLONAL HEMATOPOIETIC BLOOD DISORDERS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230114205-A1 | NANOFIBER SCAFFOLDS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023010170-A1 | STABILISED COMPOSITIONS | Rumin8 Pty Ltd (AU) | 2023-02-09 | — | — | WO | disclosed |
| WO-2011082290-A2 | FORMULATIONS FROM NATURAL PRODUCTS, TURMERIC, AND ASPIRIN | ORGANOMED CORPORATION (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7959943-B2 | Solvating system and sealant for medical use in the middle or inner ear | MEDTRONICS XOMED, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2120908-A1 | SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE | Medtronic Xomed, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008097317-A1 | SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE | MEDTRONIC XOMED, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
| US-20080195037-A1 | Film forming polymeric sealant for medical use | MEDTRONIC XOMED, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20070264310-A1 | SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE IN THE MIDDLE OR INNER EAR | MEDTRONIC, INC. | 2007-11-15 | — | — | US | disclosed |
| US-20070264342-A1 | SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE IN THE SINUSES AND NASAL PASSAGES | MEDTRONIC, INC. | 2007-11-15 | — | — | US | disclosed |
| US-4323558-A | ANTIINFLAMMATORY FOR TREATING SKIN DISORDERS, TRIETHYLENETETRAMINE | NELSON RESEARCH & DEVELOPMENT CO. (US) | 1982-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070264342-A1 | SOLVATING SYSTEM AND SEALANT FOR MEDICAL USE IN THE SINUSES AND NASAL PASSAGES | MMP7, CFTR, MMP10 | NR3C1 2359/4885PGR 3077/4885LMNA 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.